NASDAQ$SMLR

Semler Scientific Inc · Q2 2022 earnings

Q2 2022 earnings · · Investor relations

Briefing

Semler Scientific's Q2 2022 financial results were reported, showing revenue increase and profitability.

Semler Scientific reported a 4% increase in revenue to $14.8 million and a net income of $4.1 million for Q2 2022. The company achieved record revenues and cash generation due to increased orders for QuantaFlo®.

  • Revenues increased by 4% to $14.8 million compared to Q2 2021.
  • Net income was $4.1 million, or $0.51 per diluted share, compared to $6.7 million, or $0.83 per diluted share, in Q2 2021.
  • Cash and cash equivalents increased to $40.0 million as of June 30, 2022, from $28.5 million in the prior year.
  • The company is evolving into a multi-product company offering healthcare solutions to an expanding client base.

Headline financials

Total Revenue

$14.8M

Previous: $14.3M+3.6%
EPS (adj)

$0.51

Previous: $0.83-38.6%
Capital Expenditures

$136K

Previous: $104K+30.8%
Free Cash Flow

$6.09M

Previous: $2.05M+197.0%
Net Income

$4.1M

Previous: $6.7M-38.8%
Operating Income

$5.18M

Previous: $6.46M-19.9%
Gross Profit

$13.9M

Previous: $13.3M+4.1%
Cash & Equivalents

$40M

Previous: $28.5M+40.4%
Total Assets

$57.6M

Previous: $46M+25.3%
Stock-Based Comp

$48K

Previous: $46K+4.3%

Revenue & EPS history

Semler Scientific · Revenue · Quarterly

$14.8M

Q2 2022+3.6%vs Q2 2021
Beat estimate in 8 of 14 quarters(57%)
ActualEstimate

Forward guidance

Semler Scientific expects continued profitability and cash generation. For the second half of 2022, Semler Scientific projects revenue to range from $29.2 million to $31.2 million, representing a growth rate of 14% to 21% compared to the second half of 2021. Operating expenses are expected to range from $22.8 million to $24.3 million.

Tailwinds

  • Continued profitability
  • Generation of cash from operating activities
  • Increased spending to support anticipated growth
  • Revenue will range from $29.2 million to $31.2 million in the second half of 2022
  • Annual revenue will range from $58.0 million to $60.0 million

Headwinds

  • Increased spending to support anticipated growth
  • Operating expenses will range from $22.8 million to $24.3 million for the second half of 2022
  • Operating expenses will range from $42.5 million to $44.0 million for the year ended December 31, 2022
  • Uncertainty created by the ongoing COVID-19 pandemic
  • Whether or not insurance plans and other customers will continue to license its cardiovascular testing products

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 6 quarterly earnings reports

Historical avg

-0.2%

Avg return

Earnings day

-2.4%

Avg return

5 days after

-5.8%

Avg return

30 days after

54%

25 / 46 earnings

Positive

+33.6%

Q4 2014

Best reaction

-33.3%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025-10.7%-16.0%-25.1%
Q2 2025-1.8%+2.0%-20.7%
Q1 2025-11.4%+17.9%-19.3%
Q4 2024+3.0%-12.4%-22.7%
Q3 2024+27.1%+29.9%+106.6%
Q2 2024-5.4%-1.7%-16.7%
Q4 2023-32.7%-36.8%-42.5%
Q3 2023+7.6%
Q2 2023+7.9%
Q1 2023+13.8%
Q4 2022+26.9%
Q3 2022-33.3%
Q2 2022+19.4%
Q1 2022-20.6%
Q4 2021-27.3%
Q3 2021-25.6%
Q2 2021-2.7%
Q1 2021+1.5%
Q4 2020+13.6%
Q3 2020+10.0%
Q2 2020-3.6%
Q1 2020-2.6%
Q4 2019+1.8%
Q3 2019+1.7%
Q2 2019+1.5%
Q1 2019-2.7%
Q4 2018+4.8%
Q3 2018-12.5%
Q2 2018+20.6%
Q1 2018+6.4%
Q4 2017+2.5%
Q3 2017+16.0%
Q2 2017-5.9%
Q1 2017+1.5%
Q4 2016+7.9%
Q3 2016-16.0%
Q2 2016+8.1%
Q1 2016-9.2%
Q4 2015-7.9%
Q3 2015+0.1%
Q2 2015-12.2%
Q1 2013+0.9%
Q4 2014+33.6%
Q3 2014-3.7%
Q2 2014-2.0%
Q1 2014+1.2%
Q4 2013
Q3 2013
Q2 2013
Q4 2012
Q3 2012

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro